Cargando…

Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial

BACKGROUND: Identifying and reducing cardiometabolic risks driven by obesity remains a healthcare challenge. The metabolic syndrome is associated with abdominal obesity and inflammation and is predictive of long-term risk of developing type 2 diabetes and cardiovascular disease in otherwise healthy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sandsdal, Rasmus M., Juhl, Christian R., Jensen, Simon B. K., Lundgren, Julie R., Janus, Charlotte, Blond, Martin B., Rosenkilde, Mads, Bogh, Adrian F., Gliemann, Lasse, Jensen, Jens-Erik B., Antoniades, Charalambos, Stallknecht, Bente M., Holst, Jens J., Madsbad, Sten, Torekov, Signe S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960425/ https://www.ncbi.nlm.nih.gov/pubmed/36841762 http://dx.doi.org/10.1186/s12933-023-01765-z

Ejemplares similares

Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet
por: Jensen, Simon Birk Kjær, et al.
Publicado: (2019)

Insufficient sleep predicts poor weight loss maintenance after 1 year
por: Bogh, Adrian F, et al.
Publicado: (2022)

Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment
por: Jensen, Simon Birk Kjær, et al.
Publicado: (2022)

Sperm count is increased by diet-induced weight loss and maintained by exercise or GLP-1 analogue treatment: a randomized controlled trial
por: Andersen, Emil, et al.
Publicado: (2022)

Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss
por: Iepsen, E W, et al.
Publicado: (2015)

GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report
por: Iepsen, Eva W., et al.
Publicado: (2020)

Glucose-Dependent Insulinotropic Polypeptide May Enhance Fatty Acid Re-esterification in Subcutaneous Abdominal Adipose Tissue in Lean Humans
por: Asmar, Meena, et al.
Publicado: (2010)

Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual β-Cell Function
por: Kielgast, Urd, et al.
Publicado: (2011)

A Pilot Study Showing Acute Inhibitory Effect of GLP‐1 on the Bone Resorption Marker CTX in Humans
por: Nissen, Anne, et al.
Publicado: (2019)

The Antiresorptive Effect of GIP, But Not GLP‐2, Is Preserved in Patients With Hypoparathyroidism—A Randomized Crossover Study
por: Skov‐Jeppesen, Kirsa, et al.
Publicado: (2021)

Proteomics reveals the effects of sustained weight loss on the human plasma proteome
por: Geyer, Philipp E, et al.
Publicado: (2016)

Health care professionals from developing countries report educational benefits after an online diabetes course
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2017)

Neprilysin activity is increased in metabolic dysfunction-associated steatotic liver disease and normalizes after bariatric surgery or GLP-1 therapy
por: Kjeldsen, Sasha A.S., et al.
Publicado: (2023)

Increased oral sodium chloride intake in humans amplifies selectively postprandial GLP‐1 but not GIP, CCK, and gastrin in plasma
por: Asmar, Ali, et al.
Publicado: (2020)

Effect of exercise training on skeletal muscle protein expression in relation to insulin sensitivity: Per‐protocol analysis of a randomized controlled trial (GO‐ACTIWE)
por: Bruhn, Lea, et al.
Publicado: (2021)

Sweet Taste Receptor Activation in the Gut Is of Limited Importance for Glucose-Stimulated GLP-1 and GIP Secretion
por: Saltiel, Monika Y., et al.
Publicado: (2017)

Habitual physical activity is associated with lower fasting and greater glucose-induced GLP-1 response in men
por: Janus, Charlotte, et al.
Publicado: (2019)

N‐terminal alterations turn the gut hormone GLP‐2 into an antagonist with gradual loss of GLP‐2 receptor selectivity towards more GLP‐1 receptor interaction
por: Gabe, Maria Buur Nordskov, et al.
Publicado: (2022)

The effect of DPP-4-protected GLP-1 (7–36) on coronary microvascular function in obese adults
por: Nilsson, Malin, et al.
Publicado: (2019)

Effects of Exercise Domain and Intensity on Sleep in Women and Men with Overweight and Obesity
por: Quist, Jonas Salling, et al.
Publicado: (2019)

Primary weight loss failure after Roux-en-Y gastric bypass is characterized by impaired gut-hormone mediated regulation of food intake
por: Bojsen-Møller, Kirstine Nyvold, et al.
Publicado: (2023)

What is Diabetes Remission?
por: Holst, Jens J., et al.
Publicado: (2021)

Postprandial Diabetic Glucose Tolerance Is Normalized by Gastric Bypass Feeding as Opposed to Gastric Feeding and Is Associated With Exaggerated GLP-1 Secretion: A case report
por: Dirksen, Carsten, et al.
Publicado: (2010)

Acute effects of glucagon‐like peptide‐1, GLP‐1(9–36 amide), and exenatide on mesenteric blood flow, cardiovascular parameters, and biomarkers in healthy volunteers
por: Bremholm, Lasse, et al.
Publicado: (2017)

Effects of Manipulating Circulating Bile Acid Concentrations on Postprandial GLP-1 Secretion and Glucose Metabolism After Roux-en-Y Gastric Bypass
por: Jonsson, Isabella, et al.
Publicado: (2021)

The IBD-FITT study — moderate-intensity exercise for patients with inflammatory bowel disease with moderate disease activity: an open-label randomized controlled trial
por: Lund, Ken, et al.
Publicado: (2023)

Novel agonist and antagonist radioligands for the GLP‐2 receptor. Useful tools for studies of basic GLP‐2 receptor pharmacology
por: Gadgaard, Sarina, et al.
Publicado: (2022)

Exploring the GLP-1–GLP-1R axis in porcine pancreas and gastrointestinal tract in vivo by ex vivo autoradiography
por: Manell, Elin, et al.
Publicado: (2021)

Increased Body Weight and Fat Mass After Subchronic GIP Receptor Antagonist, but Not GLP-2 Receptor Antagonist, Administration in Rats
por: Baldassano, Sara, et al.
Publicado: (2019)

Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual β-Cell Function
por: Kielgast, Urd, et al.
Publicado: (2011)

Acute Effects of Dietary Carbohydrate Restriction on Glycemia, Lipemia and Appetite Regulating Hormones in Normal-Weight to Obese Subjects
por: Samkani, Amirsalar, et al.
Publicado: (2018)

Rare Heterozygous Loss-of-Function Variants in the Human GLP-1 Receptor Are Not Associated With Cardiometabolic Phenotypes
por: Melchiorsen, Josefine U, et al.
Publicado: (2023)

From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy
por: Holst, Jens Juul
Publicado: (2019)

Protocol for a single-centre, parallel-group, randomised, controlled, superiority trial on the effects of time-restricted eating on body weight, behaviour and metabolism in individuals at high risk of type 2 diabetes: the REStricted Eating Time (RESET) study
por: Quist, Jonas S, et al.
Publicado: (2020)

CCK‐1 and CCK‐2 receptor agonism do not stimulate GLP‐1 and neurotensin secretion in the isolated perfused rat small intestine or GLP‐1 and PYY secretion in the rat colon
por: Modvig, Ida M., et al.
Publicado: (2020)

Gain-of-function mutation in the voltage-gated potassium channel gene KCNQ1 and glucose-stimulated hypoinsulinemia - case report
por: Zhang, Jinyi, et al.
Publicado: (2020)

Chenodeoxycholic acid stimulates glucagon‐like peptide‐1 secretion in patients after Roux‐en‐Y gastric bypass
por: Nielsen, Signe, et al.
Publicado: (2017)

GLP-1 and Intestinal Diseases
por: Hunt, Jenna Elizabeth, et al.
Publicado: (2021)

SAT032 Circulating Neprilysin Activity Is Increased In Type 2 Diabetes And Fatty Liver Disease, And Reduces Following Bariatric Surgery And Liraglutide Therapy
por: Sampson Kjeldsen, Sasha Alexandra, et al.
Publicado: (2023)

What combines best with GLP-1 for obesity treatment: GIP receptor agonists or antagonists?
por: Holst, Jens Juul
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jc5uv487lkl7i7p7gipjkfqbsq